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Abstract
Background:  Research in infectious disease control is heavily skewed towards high end
technology; development of new drugs, vaccines and clinical interventions. Oft ignored, is the
evidence to inform the best strategies that ensure the embedding of interventions into health
systems and amongst populations. In this paper we undertake an analysis of the challenge in the
development of research for the sustainable implementation of disease control interventions.
Results: We highlight the fundamental differences between the research paradigms associated
with the development of technologies and interventions for disease control on the one hand and
the research paradigms required for enhancing the sustainable uptake of those very same
interventions within the communities on the other. We provide a definition for implementation
research in an attempt to underscore its critical role and explore the multidisciplinary science
needed to address the challenges in disease control.
Conclusion: The greatest value for money in health research lies in the sustainable and effective
implementation of already proven, efficacious solutions. The development of implementation
research that can help provide some solutions on how this can be achieved is sorely needed.
Background
Communicable diseases in general and parasitic and
infectious diseases in particular thrive because they
exploit human behaviour, and the nature of the environ-
ment, societies and culture. In the poorest regions of the
world, persistent poverty, poor living conditions and envi-
ronmental factors enhance the success of these diseases
which continue to be a major health burden. Moreover,
social, economic and political inequalities interact in
complex ways to affect vulnerability, access to treatment,
and the sequelae of disease. Poverty and its associated
social, cultural and environmental contexts are also the
critical, overarching factors that influence the impact and
instrumental value of interventions including their
acceptability, accessibility, affordability and sustainabil-
ity.
Research is a significant part of the strategy for the control
of communicable diseases with the largest tranche of
funding going to the development of new drugs, vaccines
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and clinical interventions. Success, particularly in drug
and vaccine development, is unfortunately slow and fail-
ure is expensive [1]. Nonetheless, high-end technology
continues to capture the imagination of funding bodies,
in part because it is based on methodologies that are 'tried
and true', including established research tools to demon-
strate efficacy and the econometric techniques of cost
effectiveness. It is also an area of investment that holds
potential for direct economic return based on the sale of
the developments [2]. However, at least as critical in the
product development cycle (see figure 1) is the step, often
ignored in public health, that lies between the ascertain-
ment of effectiveness and the final sustained adoption of
an intervention [3-5]. This is underscored by the fact that
interventions currently exist for many high burden dis-
eases but the conditions persist because of a failure in the
uptake of the interventions by the communities that most
need them. Indeed we would argue that even a single iter-
ation of the product development cycle is not complete
until (i) it has been scaled up to the end users and (ii)
there is a further opportunity to contribute to ongoing
product developments.
In this paper, we present an analysis of the challenges
posed by those less well developed segments of the devel-
opment cycle; the research for sustainable implementa-
tion of disease control interventions. We highlight the
fundamental differences between the research paradigms
associated with the development of technologies and
interventions for disease control on the one hand, and the
research paradigms required for enhancing the sustaina-
ble uptake of those very same interventions on the other.
We provide a definition for implementation research in
an attempt to emphasize its critical role and highlight the
multidisciplinary science needed to address the challenges
in disease control. We conclude by noting some key areas
for attention.
Product development, efficacy and effectiveness: Analyses 
in isolation
Science has traditionally been seen to advance in virtue of
our ability to make inferences about causal relationships
once extraneous, associated factors have been taken into
account. The strongest, most persuasive evidence of a
causal relationship comes from experiments in which
most factors are held constant, and only those few factors
Product Development Cycle... Figure 1
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under investigation for their causal properties are isolated
and systematically manipulated. At one end of the health
technologies development spectrum, researchers have
almost complete control over the experimental environ-
ment by creating the "ideal conditions" in which to estab-
lish a cause-effect relationship. As the drug or product
progresses into human trials, researchers forsake more
and more physical control of the experimental environ-
ment for statistical control. The intention however,
remains constant; to be in a position to analyze the causal
effect of the factors of interest (the intervention) in isola-
tion from the effects of any extraneous factors. This prin-
ciple of analysis in isolation underlies the methodology
for clinical trials to determine the efficacy of treatments,
cures and preventive measures for disease control.
Once the efficacy  of an intervention is established, the
focus of research shifts to effectiveness: the causal relation-
ship between the intervention and the outcome in
humans in routine clinical care. The principle of analysis
in isolation remains, although the researchers' capacity to
actually ensure it decreases.
Unfortunately, knowing that a treatment is effective in
routine clinical care is still insufficient, particularly in
resource poor settings. The goal for rolling out treatments
for infectious and parasitic disease control programs must
be the sustainable adoption of the intervention by the
health systems and the target population, and not simply
the establishment of effectiveness in a monitored clinical
population. In other words, an intervention must become
embedded; firmly integrated as part of the health system
and the health culture of the disease endemic setting. It
must be available, acceptable, accessible and affordable to
those who need it; used appropriately, and become a part
of the disease prevention, treatment seeking culture.
Where relevant, the intervention program must become
institutionalised regardless of organisational or political
change [6]. Interventions become embedded not by
understanding cause-effect relationships in isolation from
extraneous factors. Interventions become embedded
through the manipulation of these contextual factors that
enhance the sustainability, uptake and performance of the
intervention. The noise – that is the factors that need to be
'controlled' in efficacy and effectiveness research – thus
becomes the signal to be understood in implementation
research.
Embedding interventions: Analyses in context
Understanding the complexity of factors that affect
whether efficacious and effective interventions become
embedded is a necessary and a critical part of a complete
product development cycle. However, this phase of the
cycle, which falls under the rubric of 'implementation
research', is deplorably underdeveloped in public health.
A major review of implementation research within the
context of public policy found that it is considered a well
researched and relevant area in disciplines such as politics,
public policy and public administration [7]. However
publication is so diffuse across disciplines (including
health related disciplines) that there is still no coherent
body of knowledge or theoretical framework to define it
[7]. This is partly due to the lack of a clear definition and
operationalisation of implementation research. We define
implementation research in this context as:
applied research that aims to develop the critical evi-
dence base that informs the effective, sustained and
embedded adoption of interventions by health sys-
tems and communities. It deals with the knowledge
gap between efficacy, effectiveness and current practice
to produce the greatest gains in disease control.
Implementation research involves the systematic and crit-
ical investigation and analysis of the dynamic, contextual
processes that influence how individuals, populations
and health systems change in order to adopt new technol-
ogies and interventions. The focus begins conceptually
with an intervention which (from efficacy and effective-
ness trials) is expected to deliver health gains, and system-
atically describes and analyses the process and outcomes
from pre-intervention to successful adoption or indeed
failure of the program, through the development and test-
ing of approaches that support the scale up of disease con-
trol programs.
Historically, underutilisation of implementation research
in public health arose because (a) the development cycle
for parasitic and infection disease interventions typically
only included efficacy and effectiveness; (b) implementa-
tion research does not have the status of a 'serious' science
(marking a dispute over disciplinary boundaries and terri-
tory) [7]; (c) as a consequence of (a) and (b) when imple-
mentation research is deployed, it is on an ad hoc basis
and not as part of a coherent strategy for disease control;
and (d) as a result of the complex factors that define the
reality of embedding interventions, the outcomes can
often not be as clearly specified as outcomes resulting
from analyses in isolation [6]. Furthermore, implementa-
tion research is seen as expensive and therefore does not
attract funding and findings are often seen as contextually
specific and therefore not generalisable.
Challenges in the development of implementation 
research for infectious disease control
There is a growing recognition of the need to move from
research to practice in the area of health technologies and
clinical guidelines [8,9]. Translational research is a con-
cept similar to implementation research and is used more
commonly in the health literature. It is used in the contextBMC Public Health 2008, 8:343 http://www.biomedcentral.com/1471-2458/8/343
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of translating basic laboratory based sciences to clinical
application (bench to bedside) and in clinical practice
guidelines [10]. It has also been used to describe tools for
monitoring the process from efficacy to effectiveness trials
[11-14]. In the context of resource poor settings, it has
been used to describe the scale up of the delivery of treat-
ment to HIV positive patients [15]. Sanders and Haines
use the term implementation research and describe it as a
subset of health systems research, locating it within the
broader framework of evaluation research and focusing
on how to promote the uptake and successful execution of
evidence-based interventions and policies that have been
identified through systematic reviews [5]. Similarly, in the
editorial of the inaugural issue of Implementation Sci-
ence, Eccles describes implementation research as scien-
tific study of methods to promote the systematic uptake of
research findings and other evidence-based practices into
routine practice, and, hence, to improve the quality and
effectiveness of health services and care [16]. While these
approaches highlight progress in enhancing the signifi-
cance of implementation as part of the product develop-
ment cycle, there remains an almost exclusive focus on
effectiveness and therefore on the delivery of personal
health services. This focus continues to exclude the com-
plexities of the broader context in dealing with popula-
tion health and interventions that address access, equity,
community engagement, empowerment and participa-
tion. They also do not take account of the broader issues
of global and national contexts and the influences on pol-
icy, logistics of supply, local economies and broader
health systems all of which are critical components to
ensure embedding. Product developers need to take this
seriously, because an effective intervention that cannot
become embedded is a waste of resources which are invar-
iably limited.
We would argue that implementation research for para-
sitic and infectious disease control, involves much more
than a form of social or health program evaluation [5,17].
The problem is illustrated with tuberculosis control. The
directly observed therapy, short-course (DOTS) strategy
has been the key intervention for tuberculosis control pro-
moted by the WHO since 1991. It consists of a package of
separate interventions: detection of smear positive pul-
monary tuberculosis, directly observed chemothearapy,
guaranteed drug supply and a tracking of compliance and
outcomes.
It is a vertical program with a single disease focus which
should make it amenable to analysis in isolation. How-
ever, like many public health interventions, it is also a
complex intervention because it relies on more than one
"technology" each with a different set of extraneous varia-
bles and each introduced at different points in time by dif-
ferent sectors of the health system. It involves the
willingness and ability of governments to adopt the policy
recommendations, which in turn depend on, amongst
other things, a range of political and economic factors. It
involves the existence of a functioning health system
which means human and physical infrastructure, a guar-
anteed supply chain of diagnosistics and treatment, a
workforce able to undertake surveillance and service pro-
vision based on recommended guidelines, a regulation of
the private sector should they be involved in the national
health system and so on. There are also issues of access for
the target population that include physical, geographic,
social, cultural, economic factors that may enhance or
impede their ability to actively seek diagnosis and treat-
ment. Evaluation of the outcomes based on the standard
measures is therefore difficult and despite being one of the
longest running interventions in global health, there is no
definitive data on the effectiveness of DOTS as an inter-
vention [18]. More specifically, in the absence of the
implementation research data and an analysis of the proc-
ess [19], tuberculosis remains a major burden and further
advances in the control effort are constrained.
Guldbransoon (2008) offers a framework for exploring
the implementation process. The key concepts suggested
are the intervention or product; the decision to adopt the
product (for our purposes the policy development proc-
ess); the planning toward the change and integration
which also requires an analysis of resources; the change,
signifying an increase in the level of knowledge, and a
change in organisational capacity and finally an integra-
tion and institutionalisation of the intervention [p14].
Other models and frameworks exist [20] but these have
been developed largely on the basis of single interven-
tions. The area clearly needs major inputs to determine
how to apply lessons across contexts [21].
Implementation research provides fertile ground for the
development of interdisciplinary science across several
disciplines of applied social sciences in public health. Bor-
rowing from these multidisciplinary approaches, imple-
mentation research involves multiple methods: multilevel
case studies on the feasibility of implementation, cultural
and social relations in the community; appropriate target-
ing of limited resources, practice and policy factors, exter-
nal influences, other health, social and development
priorities, and monitoring and evaluation of processes
and economic drivers. It also involves the analysis of
intra-governmental issues around power and responsibil-
ity, as well as the relationships between government and
non-government agencies and donors. These describe
what should be a seamless link between research and con-
trol programmes.
The need for interdisciplinary approaches in implementa-
tion research is illustrated in a number of the successesBMC Public Health 2008, 8:343 http://www.biomedcentral.com/1471-2458/8/343
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and failures of tropical disease control programs. The effi-
cacy and effectiveness of insecticide impregnated bed nets
and curtains are a case in point. Phase III clinical trials in
the early 1990s in "community health laboratories" dem-
onstrated success in reducing mortality from malaria and
morbidity and from a number of other vector borne con-
ditions [22-24]. Ongoing monitoring also showed that
the 17% reduction in mortality persisted in controlled
communities seven years after the introduction of the
intervention [25]. However, embedding insecticide
impregnated bed nets and curtains outside these clinical
trials sites continues to meet with only limited success
[26].
Anthropological research has highlighted the social, eco-
nomic and cultural constraints on bed net usage that is so
important to sustainable uptake in the broader commu-
nity [27]. From the disciplinary perspective of health eco-
nomics research, the critical need to understand and
account for contextual factors in bed-net uptake is high-
lighted through studies in health financing, cost effective-
ness [28] and willingness-to-pay [29].
Health psychology and health promotion approaches
have been used to influence factors that enhance the
acceptability of interventions through social marketing
[30]. Involving communities in decision making, again
through the use of a range of social research methods, has
been important in the implementation of home manage-
ment of malaria in children. In a project that involved
mothers in the design of medication packs appropriate to
the literacy level of women in the community, for
instance, Chinibua et al found that they were able to over-
come the ongoing problem of compliance [31]. Working
with communities has also been a key factor in the suc-
cessful fight against river blindness.
Discussion
The need for implementation research has been recog-
nized [5,32-34] although the explicit support in global
health has been slow and there has been limited engage-
ment with product developers. Limited ad hoc funding is
often provided for social science components of research
and disease control programs, but these are inevitably as
adjunct research to the "more serious" effectiveness
research. While this may be useful for specific cases, the
ultimate goal of implementation research needs to be the
development of an evidence base which would allow
some generalization beyond individual communities and
enable predictions to be made about how well interven-
tions would be embedded given particular conditions.
The science of implementation research needs to be devel-
oped as an integrated package that promotes engagement
between researchers in product development and the
social scientists, disease control personnel and communi-
ties that will benefit from the interventions.
Development of capacity in this area has to be a critical
component of the renewed commitment to tackle
neglected parasitic and infectious diseases. The Special
Programme for Research and Training in Tropical Dis-
eases (TDR) has supported the development of training at
different levels of capacity [35] in Ghana and Kenya to
enable researchers from endemic countries to develop not
only the theoretical and research skills required in imple-
mentation research, but also the leadership abilities to
address an area that is inherently political and challenging
(not least because of demarcation and guild motivated
disputes between disciplines). These programs are further
supported by short courses to train field researchers and
the potential future workforce in implementation
research.
Conclusion
The benchmark statement of the Declaration of Alma Ata
provides a cogent argument for evidence based solutions
that are practical, socially acceptable, accessible, and avail-
able at a cost that is sustainable. A commitment to allevi-
ating the burden of parasitic and infectious diseases in
resource poor settings is incomplete if it is does not close
the product development cycle, from the basic sciences to
the embedding of interventions. The greatest value for
money in health research lies in the sustainable and effec-
tive implementation of already proven, efficacious solu-
tions and less in the development of new tools and
products for which the implementation research remains
to be done. The development of the research that can help
provide some solutions on how this can be achieved is
sorely needed [21].
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